Noninvasive theranostic imaging of HSV1-sr39TKNTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice

Theranostics

Volumn 4, Issue 5, 2014, Pages 460-474

  Sekar, Thillai V ^a   Foygel, Kira ^a   Ilovich, Ohad ^a   Paulmurugan, Ramasamy ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Gene directed enzyme prodrug therapy; Theranostic imaging; Tumor monitoring

Indexed keywords

GANCICLOVIR; PENCICLOVIR; TRETAZICAR; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG UPTAKE; ENZYME THERAPY; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE ANALYSIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOBLOTTING; LUNG METASTASIS; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PLASMID; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

GENE-DIRECTED ENZYME PRODRUG THERAPY; THERANOSTIC IMAGING; TUMOR MONITORING;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GLUTAMINE; LUNG NEOPLASMS; MICE; NEOPLASM METASTASIS; NITROREDUCTASES; OPTICAL IMAGING; ORGANOMETALLIC COMPOUNDS; PRODRUGS; THYMIDINE KINASE; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902436272     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8077     Document Type: Article

References (35)

1. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang DY, et al. Distant metastasis in triple-negative breast cancer. Neoplasma. 2013; 60: 290-4.
2. Mailly L, Leboeuf C, Tiberghien P, Baumert T, Robinet E. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr Opin Investig Drugs. 2010; 11: 559-70.
3. Morris JC, Ramsey WJ, Wildner O, Muslow HA, Aguilar-Cordova E, Blaese RM. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther. 2000; 11: 487-503.
4. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol Ther. 2009; 17: 1292-9.
5. Searle PF, Chen MJ, Hu L, Race PR, Lovering AL, Grove JI, et al. Nitroreductase:a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol. 2004; 31: 811-6.
6. Knox RJ. Gene-directed enzyme prodrug therapy (GDEPT)--recognizing the present limitations of gene therapy for the treatment of cancer. Curr Opin Investig Drugs. 2001; 2: 835-8.
7. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine:a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A. 1983; 80: 4139-43.
8. Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite. Hum Gene Ther. 1997; 8: 709-17.
9. Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H, et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998; 18: 3399-406.
10. Nicholas TW, Read SB, Burrows FJ, Kruse CA. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol. 2003; 18: 495-507.
11. McNeish IA, Tenev T, Bell S, Marani M, Vassaux G, Lemoine N. Herpes simplex virus thymidine kinase/ganciclovir-induced cell death is enhanced by co-expression of caspase-3 in ovarian carcinoma cells. Cancer Gene Ther. 2001; 8: 308-19.
12. Jones RK, Pope IM, Kinsella AR, Watson AJ, Christmas SE. Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 2000; 7: 1519-28.
13. Young JG, Green NK, Mautner V, Searle PF, Young LS, James ND. Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis. 2008; 11: 187-93.
14. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001; 8: 1547-54.
15. Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res. 2003; 63: 6847-54.
16. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively:concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther. 1998; 9: 1323-33.
17. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther. 1997; 8: 73-85.
18. Barton KN, Paielli D, Zhang Y, Koul S, Brown SL, Lu M, et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther. 2006; 13: 347-56.
19. Bhaumik S, Sekar TV, Depuy J, Klimash J, Paulmurugan R. Noninvasive optical imaging of nitroreductase gene-directed enzyme prodrug therapy system in living animals. Gene Ther. 2012; 19: 295-302.
20. Sekar TV, Foygel K, Willmann JK, Paulmurugan R. Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging. Gene Ther. 2013; 20: 529-37.
21. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009; 6: 53-8.
22. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007; 48: 932-45.
23. Ray P, Tsien R, Gambhir SS. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res. 2007; 67: 3085-93.
24. Shu CJ, Radu CG, Shelly SM, Vo DD, Prins R, Ribas A, et al. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol. 2009; 21: 155-65.
25. Barinoff J, Hils R, Bender A, Gross J, Kurz C, Tauchert S, et al. Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without:a multicentre study. Eur J Cancer. 2013; 49: 305-11.
26. Marquette C, Nabell L. Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol. 2012; 13: 263-75.
27. Andre F, Zielinski CC. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol. 2012;23 Suppl 6:vi46-51.
28. Deng WP, Wu CC, Lee CC, Yang WK, Wang HE, Liu RS, et al. Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. J Nucl Med. 2006; 47: 877-84.
29. Yu B, Zhang Y, Zhan Y, Zha X, Wu Y, Zhang X, et al. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep. 2011; 26: 255-64.
30. Rashid OM, Nagahashi M, Ramachandran S, Dumur CI, Schaum JC, Yamada A, et al. Is tail vein injection a relevant breast cancer lung metastasis model? J Thorac Dis. 2013;5:385-92.
31. Tjuvajev JG, Doubrovin M, Akhurst T, Cai S, Balatoni J, Alauddin MM, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002; 43: 1072-83.
32. Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000; 7: 1086-99.
33. Jang SJ, Kang JH, Kim KI, Lee TS, Lee YJ, Lee KC, et al. Application of bioluminescence imaging to therapeutic intervention of herpes simplex virus type I-Thymidine kinase/ganciclovir in glioma. Cancer Lett. 2010; 297: 84-90.
34. Jiang YX, Lu Y, Liu TJ, Yang J, Chen Y, Fang YW. Using HSV-TK/GCV suicide gene therapy to inhibit lens epithelial cell proliferation for treatment of posterior capsular opacification. Mol Vis. 2011; 17: 291-9.
35. Lifang Y, Min T, Midan A, Ya C. HSV-tk/GCV gene therapy mediated by EBV-LMP1 for EBV-associated cancer. J Exp Clin Cancer Res. 2008;27:42.